HAEMATOLOGY


only the diagnostic tools needed, but also the educational resources and advocacy required to drive adoption. Embracing early diagnosis as the most optimal solution for MM enables stakeholders to create a future where patients receive timely, life-changing care, while also alleviating the burden of late-stage disease on an already overstretched healthcare system.


References 1 National Institute for Health and Care


Excellence. Clinical Knowledge Summaries - Multiple myeloma: Prevalence. (NICE, 2022) https://cks.nice.org.uk/ topics/multiple-myeloma/background- information/prevalence


2 National Institute for Health and Care Excellence. Clinical Knowledge Summaries - When should I suspect multiple myeloma? (NICE, 2022) https:// cks.nice.org.uk/topics/multiple-myeloma/ diagnosis/when-should-i-suspect-multiple- myeloma/


3 Cancer Research UK. Symptoms of myeloma. (CRUK, 2023) https://www. cancerresearchuk.org/about-cancer/ myeloma/symptoms


4 Myeloma UK. Ask the nurse: Myeloma and blood cells. (Myeloma UK, 2020) https:// www.myeloma.org.uk/library/ask-the- nurse-myeloma-and-blood-cells/


5 International Myeloma Foundation. Types of multiple myeloma. (IMF, 2025) https:// www.myeloma.org/types-of-myeloma


6 Pandey S, Kyle RA. Unusual myelomas: a review of IgD and IgE variants. Oncology (Williston Park). 2013;27(8):798-803.


7 Brioli A, Giles H, Pawlyn C, et al. Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood. 2014;123(22):3414-3419. doi:10.1182/blood-2013-12-542662


8 Leung N, Gertz MA, Zeldenrust SR, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008;73(11):1282- 1288. doi:10.1038/ki.2008.108


9 Myeloma UK. What is myeloma? (Myeloma UK, 2025). https://www.myeloma.org. uk/understanding-myeloma/what-is- myeloma/


10 Myeloma UK. Monoclonal gammopathy of undetermined significance (MGUS). (Myeloma UK, 2025) https://www. myeloma.org.uk/understanding-myeloma/ related-conditions/mgus/


11 Ji M, Huber JH, Schoen MW, et al. Mortality in the US Populations With Monoclonal Gammopathy of Undetermined Significance. JAMA Oncol. 2023;9(9):1293-1295. doi:10.1001/ jamaoncol.2023.2278


12 Hevroni G, Vattigunta M, Kazandjian D,


Early diagnosis consistently proves to be the most effective treatment strategy, reducing tumour burden, preventing severe complications and dramatically improving prognoses


et al. From MGUS to multiple myeloma: Unraveling the unknown of precursor states. Blood Rev. 2024;68:101242. doi:10.1016/j.blre.2024.101242


13 International Myeloma Foundation. IMWG criteria for the diagnosis of multiple myeloma. (IMF, 2025) https://www. myeloma.org/international-myeloma- working-group-imwg-criteria-diagnosis- multiple-myeloma


14 International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-757.


15 Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548. doi:10.1016/ S1470-2045(14)70442-5


16 National Institute for Health and Care Excellence. Myeloma: Diagnosis and management. (NICE, 2016) https://www. nice.org.uk/guidance/ng35


17 Katzmann JA, Kyle RA, Benson J, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem. 2009;55(8):1517-1522. doi:10.1373/ clinchem.2009.126664


18 Dejoie T, Corre J, Caillon H, et al. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. Blood. 2016;128(25):2941-2948. doi:10.1182/ blood-2016-07-726778


19 Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97(9):2900-2902. doi:10.1182/blood. v97.9.2900


20 Sive J, Cuthill K, Hunter H, et al. Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline. Br J Haematol. 2021;193(2):245-268. doi:10.1111/ bjh.17410


21 Cancer Research UK. Survival for myeloma. (CRUK, 2023) https://www. cancerresearchuk.org/about-cancer/ myeloma/survival


22 Bong IPN, Esa E. Molecular genetic aberrations in the pathogenesis of multiple


WWW.PATHOLOGYINPRACTICE.COM MAY 2025


myeloma. Asian Biomed (Res Rev News). 2023 Oct 18;17(4):152-162. doi:10.2478/ abm-2023-0056


23 Porteous A, Gibson S, Eddowes LA, et al. An Economic Model to Establish the Costs Associated With Routes to Presentation for Patients With Multiple Myeloma in the United Kingdom. Value Health Reg Issues. 2023;35:27-33. doi:10.1016/j. vhri.2023.01.001


24 Kariyawasan CC, Hughes DA, Jayatillake MM, Mehta AB. Multiple myeloma: causes and consequences of delay in diagnosis. QJM. 2007;100(10):635-640. doi:10.1093/qjmed/hcm077


25 Pellegrini E. Driving diagnosis: Myeloma UK partners with Costello medical to highlight the cost of delayed myeloma diagnosis. (Myeloma UK, 2021) https:// www.myeloma.org.uk/news/driving- diagnosis-myeloma-uk-partners-with- costello-medical-to-highlight-the-cost-of- delayed-myeloma-diagnosis/


26 Raleigh V. The health of people from ethnic minority groups in England. (The King’s Fund., 2023) https://www.kingsfund. org.uk/insight-and-analysis/long-reads/ health-people-ethnic-minority-groups- england


27 Myeloma UK. Ask the nurse: Black people and myeloma. (Myeloma UK, 2023) https://www.myeloma.org.uk/library/ask- the-nurse-black-people-and-myeloma/


28 Myeloma UK. Early diagnosis programme. (Myeloma UK, 2025) https://www. myeloma.org.uk/research-and-impact/ panels-and-advisory-groups/early- diagnosis-programme/


Dale Powner is the Country Manager for the UK, Ireland and Nordics at Binding Site, part of Thermo Fisher Scientific, a company that provides products and solutions for diagnosing and monitoring blood cancers and immune system disorders. Since joining the company in 2010, Dale has held diverse roles, from Medical Science Liaison to Business Development Manager. He now leads regional operations, focusing on advancing diagnostics, promoting early detection and improving patient outcomes, particularly in multiple myeloma and related conditions.


Optilite and Freelite are registered trademarks of The Binding Site Group (Birmingham, UK) in certain countries.


www.thermofisher.com/bindingsite 51


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56